Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)
June 15, 2020 08:19 ET
|
Arch Biopartners
International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
June 08, 2020 07:00 ET
|
Arch Biopartners
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19
May 19, 2020 16:31 ET
|
Arch Biopartners
TORONTO, May 19, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
May 08, 2020 06:00 ET
|
Arch Biopartners
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model
March 31, 2020 07:36 ET
|
Arch Biopartners
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL DRUG CANDIDATES TO PREVENT LUNG INFLAMMATION
March 24, 2020 07:27 ET
|
Arch Biopartners
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies
March 04, 2020 09:56 ET
|
Arch Biopartners
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok...
Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial
December 18, 2019 09:27 ET
|
Arch Biopartners
TORONTO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury
December 04, 2019 08:46 ET
|
Arch Biopartners
TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
August 22, 2019 12:24 ET
|
Arch Biopartners
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....